Hirohiko Shibayama

4.8k citations

123 papers · 2.2k indexed · h-index 25

Hematology top 1%
- Acute Myeloid Leukemia Research 26
- Chronic Myeloid Leukemia Treatments 19
- Multiple Myeloma Research and Treatments 17
- Hematopoietic Stem Cell Transplantation 15
Genetics top 2%
- Chronic Lymphocytic Leukemia Research 25
Immunology top 5%
Immunology and Allergy top 5%
Oncology top 5%
- Viral-associated cancers and disorders 11
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 21
Rheumatology
- Eosinophilic Disorders and Syndromes 12

Co-authors: Yuzuru Kanakura Itaru Matsumura Masao Mizuki Sachiko Ezoe Hirokazu Tanaka Takashi Machii Yusuke Satoh Hal E. Broxmeyer
Cited by: Hematology Genetics Immunology
Partner nations: Japan United States South Korea

In The Last Decade

Hirohiko Shibayama

114 papers receiving 2.1k citations

Peers

Countries citing papers authored by Hirohiko Shibayama

Since Specialization

Citations

This map shows the geographic impact of Hirohiko Shibayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirohiko Shibayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirohiko Shibayama more than expected).

Fields of papers citing papers by Hirohiko Shibayama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirohiko Shibayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirohiko Shibayama. The network helps show where Hirohiko Shibayama may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hirohiko Shibayama, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hirohiko Shibayama Line = papers co-authored together Hirohiko Shibayama links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm Yasuhiro Nagate,Aya Nakaya,Ren Kamimura,Yumiko Hirose,Satoshi Nojima,Jiro Fujita,Eiji Kiyohara,Hirohiko Shibayama	2023	0
2	Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia Naohiro Sekiguchi,Shinya Rai,Wataru Munakata,Kenshi Suzuki,Hiroshi Handa,Hirohiko Shibayama,Tomoyuki Endo,Yasuhito Terui,Noriko Iwaki,Noriko Fukuhara,Hiro Tatetsu,Shinsuke Iida,Takayuki Ishikawa,Daisuke Iguchi,Koji Izutsu	2022	22
3	Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study Kazutaka Sunami,Shin‐ichi Fuchida,Kenshi Suzuki,Masaki Ri,Morio Matsumoto,Chihiro Shimazaki,Hideki Asaoku,Hirohiko Shibayama,Kenichi Ishizawa,Hiroyuki Takamatsu,Takashi Ikeda,Dai Maruyama,Kazunori Imada,Michihiro Uchiyama,Toru Kiguchi,Satoshi Iyama,Hirokazu Murakami,Reiko Onishi,Keisuke Tada,Shinsuke Iida	2022	1
4	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial Hirohisa Nakamae,Masahide Yamamoto,Emiko Sakaida,Yoshinobu Kanda,Ken Ohmine,Takaaki Ono,Itaru Matsumura,Maho Ishikawa,Makoto Aoki,Akio Maki,Hirohiko Shibayama	2021	8
5	Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study Koji Izutsu,Kiyoshi Ando,Daisuke Ennishi,Hirohiko Shibayama,Junji Suzumiya,Kazuhito Yamamoto,Satoshi Ichikawa,Koji Kato,Kyoya Kumagai,Priti Patel,Sakura Iizumi,Nobuya Hayashi,Hisashi Kawasumi,K. Murayama,Hirokazu Nagai	2021	8
6	Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial Kenshi Suzuki,Chang‐Ki Min,Kihyun Kım,Je‐Jung Lee,Hirohiko Shibayama,Po‐Shen Ko,Shang‐Yi Huang,Sin‐Syue Li,Bifeng Ding,Monica Khurana,Shinsuke Iida	2021	4
7	Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function Yasuhiro Nagate,Sachiko Ezoe,Jiro Fujita,Daisuke Okuzaki,Daisuke Motooka,Tomohiko Ishibashi,Michiko Ichii,Akira Tanimura,Masako Kurashige,Eiichi Morii,Takuya Fukushima,Youko Suehiro,Takafumi Yokota,Hirohiko Shibayama,Kenji Oritani,Yuzuru Kanakura	2020	25
8	A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia Naohiro Sekiguchi,Shinya Rai,Wataru Munakata,Kenshi Suzuki,Hiroshi Handa,Hirohiko Shibayama,Tomoyuki Endo,Yasuhito Terui,Noriko Iwaki,Noriko Fukuhara,Hiro Tatetsu,Shinsuke Iida,Takayuki Ishikawa,Ryota Shiibashi,Koji Izutsu	2020	60
9	Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML Jun Toda,Michiko Ichii,Kenji Oritani,Hirohiko Shibayama,Akira Tanimura,Hideaki Saito,Takafumi Yokota,Daisuke Motooka,Daisuke Okuzaki,Yuichi Kitai,Ryuta Muromoto,Jun‐ichi Kashiwakura,Tadashi Matsuda,Naoki Hosen,Yuzuru Kanakura	2020	13
10	Signal-transducing adaptor protein-2 delays recovery of B lineage lymphocytes during hematopoietic stress Michiko Ichii,Kenji Oritani,Jun Toda,Hideaki Saito,Henyun Shi,Hirohiko Shibayama,Daisuke Motooka,Yuichi Kitai,Ryuta Muromoto,Jun‐ichi Kashiwakura,Kodai Saitoh,Daisuke Okuzaki,Tadashi Matsuda,Yuzuru Kanakura	2020	7
11	PF462 SPECIAL AT‐RICH SEQUENCE BINDING PROTEIN 1 (SATB1) IS MARKEDLY EXPRESSED IN THE DARK ZONE GERMINAL CENTER B CELLS ON MURINE SPLEEN Takayuki Ozawa,Takafumi Yokota,Yasuhiro Shingai,Tomoaki Ueda,Yukiko Doi,Hirohiko Shibayama,Yuzuru Kanakura	2019	0
12	Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study Shinsuke Iida,Takashi Watanabe,Morio Matsumoto,Kenshi Suzuki,Kazutaka Sunami,Tadao Ishida,Kiyoshi Ando,Takaaki Chou,Shuji Ozaki,Masafumi Taniwaki,Naokuni Uike,Hirohiko Shibayama,Kiyohiko Hatake,Koji Izutsu,Takayuki Ishikawa,Yoshihisa Shumiya,Kensei Tobinai	2019	6
13	Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial Yasuyoshi Morita,Yasuhiro Maeda,Terufumi Yamaguchi,Fumiaki Urase,Shuhei Kawata,Hitoshi Hanamoto,Kazuo Tsubaki,Jun Ishikawa,Hirohiko Shibayama,Itaru Matsumura,Mitsuhiro Matsuda	2018	10
14	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial Hirohisa Nakamae,Tetsuya Fukuda,Chiaki Nakaseko,Yoshinobu Kanda,Ken Ohmine,Takaaki Ono,Itaru Matsumura,Akira Matsuda,Makoto Aoki,Kazuo Itô,Hirohiko Shibayama	2017	21
15	ESAM is a novel human hematopoietic stem cell marker associated with a subset of human leukemias Tomohiko Ishibashi,Takafumi Yokota,Hirokazu Tanaka,Michiko Ichii,Takao Sudo,Yusuke Satoh,Yukiko Doi,Tomoaki Ueda,Akira Tanimura,Yuri Hamanaka,Sachiko Ezoe,Hirohiko Shibayama,Kenji Oritani,Yuzuru Kanakura	2016	22
16	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily Timothy P. Hughes,Andreas Hochhaus,Hagop M. Kantarjian,Francisco Cervantes,François Guilhot,Dietger Niederwieser,Phillipp D. Le Coutre,G Rosti,G. J. Ossenkoppele,Clarisse Lobo,Hirohiko Shibayama,Xingwen Fan,Hans D. Menssen,Charisse Kemp,Richard A. Larson,Giuseppe Saglio	2014	37
17	Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd Hirohisa Nakamae,Hirohiko Shibayama,Mineo Kurokawa,Tetsuya Fukuda,Chiaki Nakaseko,Yoshinobu Kanda,Tadashi Nagai,Kazunori Ohnishi,Yasuhiro Maeda,Akira Matsuda,Taro Amagasaki,Masamitsu Yanada	2011	15
18	Peripheral T-cell lymphoma of Lennert type complicated by monoclonal proliferation of large B-cells Takeshi Chihara,Naoki Wada,Masaharu Kohara,Takako Matsui,Hiroaki Masaya,Tetsuo Maeda,Hirohiko Shibayama,Yuzuru Kanakura,Mamori Tani,Eiichi Morii,Katsuyuki Aozasa	2009	4
19	Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells Hironobu Kimura,Eiichi Morii,J-i Ikeda,Sachiko Ezoe,Jixiong Xu,Naoto Nakamichi,Yasuhiko Tomita,Hirohiko Shibayama,Yuzuru Kanakura,K Aozasa	2006	10
20	Notch Signals Inhibit the Development of Erythroid/Megakaryocytic Cells by Suppressing GATA-1 Activity through the Induction of HES1 Eri Ishiko,Itaru Matsumura,Sachiko Ezoe,Karin B. Gale,Jun Ishiko,Yusuke Satoh,Hirokazu Tanaka,Hirohiko Shibayama,Masao Mizuki,Takumi Era,Tariq Enver,Yuzuru Kanakura	2004	68

About Hirohiko Shibayama

Hirohiko Shibayama is a scholar working on Hematology, Genetics and Immunology, having authored 123 papers that have together received 2.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (26 papers), Chronic Lymphocytic Leukemia Research (25 papers), Lymphoma Diagnosis and Treatment (21 papers), Chronic Myeloid Leukemia Treatments (19 papers), Multiple Myeloma Research and Treatments (17 papers), Hematopoietic Stem Cell Transplantation (15 papers), Eosinophilic Disorders and Syndromes (12 papers) and Viral-associated cancers and disorders (11 papers). The work is most often cited by research in Hematology (783 citations), Genetics (501 citations) and Immunology (495 citations). Hirohiko Shibayama has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Yuzuru Kanakura, Itaru Matsumura, Masao Mizuki, Sachiko Ezoe, Hirokazu Tanaka, Takashi Machii, Yusuke Satoh, Hal E. Broxmeyer, Hiroyuki Sugahara and Eiichi Morii.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact